Trial
NCT07100925
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Ankyra Therapeutics, Inc
Collaborators
—
Condition
Cutaneous Squamous Cell Carcinoma (CSCC)
Intervention
tolododekin alfa
Why stopped
Strategic realignment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-25